medmix AG

$ 8.38 -0.36 %

Established in 1922 and headquartered in Zug, Switzerland, Medmix AG stands as a global leader in innovating, manufacturing, and distributing high-precision devices and services. These solutions are meticulously engineered for the controlled mixing, application, and injection of liquids across various viscosities, serving diverse healthcare, consumer, and industrial markets worldwide. The company operates through five key divisions: Dental, Drug Delivery, Surgery, Industry, and Beauty. The Dental segment offers essential tools such as mixing tips, dispensers, needles, and accessories, alongside support services for applications including prosthetics, restorative procedures, anesthesiology, and cosmetic dentistry. In its Drug Delivery segment, Medmix develops critical devices for administering medications like fertility drugs, growth hormones, and treatments for specific diabetes conditions, osteoporosis, and rare diseases. The Surgery segment provides specialized mixing and delivery systems utilized for injecting bone cement and applying hemostatic sealants to manage both internal and external wounds during surgical interventions. For industrial clients, the Industry division produces robust dispensers, cartridges, and mixers for two-component adhesives and sealants, indispensable in sectors such as construction, transportation, electronics, infrastructure, and broader manufacturing. Lastly, the Beauty segment supplies micro brushes, mascara applicators, lip gloss, and concealers. Medmix AG markets its comprehensive product range under well-recognized brands, including Mixpac, Transcodent, Cox, MK, Medmix, Haselmeier, and Geka.

CEO: Rene Willi - https://www.medmix.swiss

Price objectif

-

Recommandation

-

DCF

$ 13.25

Loading data...

MEDX.SW vs S&P500

Loading data...

No data available.

Quick ratio

1.10

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

55.87

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

0.15

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

1.51 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

2.65 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

5.61

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.78

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

0.82

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

234.38 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
5 indicates moderate financial health
Altman score
2.30 indicates an uncertain financial situation
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.61 indicates that the company has a moderate ability to cover its short-term debts with its cash
Debt Ratio
0.34 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.